*Rivaroxaban for acute treatment and long term secondary prevention of Venous thromboembolism
*Apixaban for the prevention of stroke and systemic arterial thrombosis in patients with non valvular Atrial Fibrillation. Apixaban 5 mg PO BID
reduce dose to 2.5 mg if patient less than 60 kg weight
Creatinine >1.5
Age >80
*Rivaroxaban approved for atrial fibrillation at 20 mg daily if GFR >50
and 15 mg if GFR between 15 and 50
No use of Riva if GFR<15
No comments:
Post a Comment